Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerd-R Burmester

Showing results (101-110 of 293) with videos related to

Pageof 30
Sort By:
Diagnostics (Basel, Switzerland)|January 8, 2023
Performance of Deauville Criteria in <sup>[18F]</sup>FDG-PET/CT Diagnostics of Giant Cell ArteritisJeffrey Siefert, Jonas Kaufmann, Felix Thiele, et al.
BMJ Open|August 4, 2021
Is the fluorescence optical imaging (FOI) able to discriminate between rheumatoid arthritis patients with and without need of rituximab retherapy? A cohort studySchahrasad Lisa Ridha Ali, Anne-Marie Glimm, Gerd R Burmester, et al.
Annals of the Rheumatic Diseases|March 11, 2016
The changing landscape of biosimilars in rheumatologyThomas Dörner, Vibeke Strand, Paul Cornes, et al.
Arthritis Research & Therapy|November 12, 2014
Active systemic lupus erythematosus is associated with a reduced cytokine production by B cells in response to TLR9 stimulationJulia Sieber, Capucine Daridon, Sarah J Fleischer, et al.
Journal of Clinical Pharmacology|September 8, 2016
Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTAHisham Abdallah, Joy C Hsu, Peng Lu, et al.
RMD Open|June 3, 2025
Benefit-risk analysis of upadacitinib versus adalimumab in patients with rheumatoid arthritis and higher or lower risk of cardiovascular diseaseGerd R Burmester, Eduardo Mysler, Peter Taylor, et al.
European Journal of Immunology|July 7, 2018
Proteasome inhibition with bortezomib induces a therapeutically relevant depletion of plasma cells in SLE but does not target their precursorsTobias Alexander, Qingyu Cheng, Jens Klotsche, et al.
Annals of the Rheumatic Diseases|March 12, 2018
Common language description of the term rheumatic and musculoskeletal diseases (RMDs) for use in communication with the lay public, healthcare providers and other stakeholders endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR)Désirée van der Heijde, David I Daikh, Neil Betteridge, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 14, 2018
Common Language Description of the Term Rheumatic and Musculoskeletal Diseases (RMDs) for Use in Communication With the Lay Public, Healthcare Providers, and Other Stakeholders Endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR)Désirée van der Heijde, David I Daikh, Neil Betteridge, et al.
Arthritis and Rheumatism|April 29, 2006
Tissue-specific up-regulation of the proteasome subunit beta5i (LMP7) in Sjögren's syndromeThomas Egerer, Lorena Martinez-Gamboa, Anja Dankof, et al.
Pageof 30

Showing results (101-110 of 293) with videos related to

Sort By:
Pageof 30
Diagnostics (Basel, Switzerland)|January 8, 2023
Performance of Deauville Criteria in <sup>[18F]</sup>FDG-PET/CT Diagnostics of Giant Cell ArteritisJeffrey Siefert, Jonas Kaufmann, Felix Thiele, et al.
BMJ Open|August 4, 2021
Is the fluorescence optical imaging (FOI) able to discriminate between rheumatoid arthritis patients with and without need of rituximab retherapy? A cohort studySchahrasad Lisa Ridha Ali, Anne-Marie Glimm, Gerd R Burmester, et al.
Annals of the Rheumatic Diseases|March 11, 2016
The changing landscape of biosimilars in rheumatologyThomas Dörner, Vibeke Strand, Paul Cornes, et al.
Arthritis Research & Therapy|November 12, 2014
Active systemic lupus erythematosus is associated with a reduced cytokine production by B cells in response to TLR9 stimulationJulia Sieber, Capucine Daridon, Sarah J Fleischer, et al.
Journal of Clinical Pharmacology|September 8, 2016
Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTAHisham Abdallah, Joy C Hsu, Peng Lu, et al.
RMD Open|June 3, 2025
Benefit-risk analysis of upadacitinib versus adalimumab in patients with rheumatoid arthritis and higher or lower risk of cardiovascular diseaseGerd R Burmester, Eduardo Mysler, Peter Taylor, et al.
European Journal of Immunology|July 7, 2018
Proteasome inhibition with bortezomib induces a therapeutically relevant depletion of plasma cells in SLE but does not target their precursorsTobias Alexander, Qingyu Cheng, Jens Klotsche, et al.
Annals of the Rheumatic Diseases|March 12, 2018
Common language description of the term rheumatic and musculoskeletal diseases (RMDs) for use in communication with the lay public, healthcare providers and other stakeholders endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR)Désirée van der Heijde, David I Daikh, Neil Betteridge, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 14, 2018
Common Language Description of the Term Rheumatic and Musculoskeletal Diseases (RMDs) for Use in Communication With the Lay Public, Healthcare Providers, and Other Stakeholders Endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR)Désirée van der Heijde, David I Daikh, Neil Betteridge, et al.
Arthritis and Rheumatism|April 29, 2006
Tissue-specific up-regulation of the proteasome subunit beta5i (LMP7) in Sjögren's syndromeThomas Egerer, Lorena Martinez-Gamboa, Anja Dankof, et al.
Pageof 30